A novel lecithin-cholesterol acyltransferase antioxidant activity prevents the formation of oxidized lipids during lipoprotein oxidation

被引:78
作者
Vohl, MC [1 ]
Neville, TAM [1 ]
Kumarathasan, R [1 ]
Braschi, S [1 ]
Sparks, DL [1 ]
机构
[1] Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada
关键词
D O I
10.1021/bi982258w
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent investigations suggest that high-density lipoprotein (HDL) may play an anti-atherogenic role as an antioxidant and inhibit the oxidative modification of low-density lipoprotein (LDL), The antioxidant activity of HDL has been proposed to be associated with several HDL-bound proteins. We have purified one HDL-associated protein, lecithin:cholesterol acyltransferase (LCAT), to apparent homogeneity and have found that LCAT is not only capable of esterifying cholesterol in the plasma, but can also prevent the accumulation of oxidized lipids in LDL. Addition of pure human LCAT to LDL or palmitoyl-linoleoyl phosphatidylcholine/sodium cholate (PLPC) micelles inhibits the oxidation-dependent accumulation of both conjugated dienes and lipid hydroperoxides. LCAT also inhibits the increase of net negative charge that occurs during oxidation of LDL. LCAT has the ability to prevent spontaneous oxidation and Cu2+ and soybean lipoxygenase-catalyzed oxidation of lipids. The antioxidant activity of LCAT appears to be enzymatic, since the enzyme is active for up to 10 h in the presence of mild free-radical generators. The catalytic serine, residue 181, may mediate this activity and act as a reusable proton donor. Chemical modification of the active serine residue with diisopropylfluorophosphate completely inhibits the ability of LCAT to prevent lipid oxidation. Thus, in addition to its well-characterized phospholipase and acyltransferase activities, LCAT can also act as an antioxidant and prevent the accumulation of oxidized lipid in plasma lipoproteins.
引用
收藏
页码:5976 / 5981
页数:6
相关论文
共 38 条
  • [1] ISOLATION AND CHARACTERIZATION OF HUMAN-PLASMA LIPID TRANSFER PROTEINS
    ALBERS, JJ
    TOLLEFSON, JH
    CHEN, CH
    STEINMETZ, A
    [J]. ARTERIOSCLEROSIS, 1984, 4 (01): : 49 - 58
  • [2] Bao YP, 1996, J LIPID RES, V37, P2351
  • [3] Bielicki JK, 1996, J LIPID RES, V37, P1012
  • [4] BONELLI FS, 1989, J BIOL CHEM, V264, P14723
  • [5] INCIDENCE OF CORONARY HEART-DISEASE AND LIPOPROTEIN CHOLESTEROL LEVELS - THE FRAMINGHAM-STUDY
    CASTELLI, WP
    GARRISON, RJ
    WILSON, PWF
    ABBOTT, RD
    KALOUSDIAN, S
    KANNEL, WB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1986, 256 (20): : 2835 - 2838
  • [6] EFFECT OF PEROXYL RADICALS ON LECITHIN-CHOLESTEROL ACYLTRANSFERASE ACTIVITY IN HUMAN PLASMA
    CHEN, C
    LOO, G
    [J]. LIPIDS, 1995, 30 (07) : 627 - 631
  • [7] COLL RJ, 1982, METHOD ENZYMOL, V87, P66
  • [8] Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase
    Dentan, C
    Tselepis, AD
    Chapman, MJ
    Ninio, E
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1996, 1299 (03): : 353 - 357
  • [9] EISENBERG S, 1984, J LIPID RES, V25, P1017
  • [10] ELSAADANI M, 1989, J LIPID RES, V30, P627